The 3D Signatures Inc. (DXD:TSX.V) platform combines minimally invasive blood tests with software that uses three-dimensional imagery of a patient's chromosomes to determine the stage of disease and zero in on the best treatment for that individual. The company updated its plans for the coming year in an Oct. 17 Letter to Shareholders.
By combining a "biotech play with a software and technology play" to generate a profile of a patient's disease, physicians are able to customize treatment plans to the individual, company CEO Jason Flowerday explained in an interview, adding the 3D Signatures technology also could provide savings for payers by avoiding the costly administration of treatments that would not be effective.
The platform is based on the discovery of "a new, complex, and dynamic class of biomarker [with] strong supporting data for fourteen different cancers and neurodegenerative diseases, in addition to drug development applications" made by the 3D Signatures 's cofounder, Dr. Sabine Mai, according to the company.
The company also announced the composition of its new scientific advisory board on Dec. 9, which Etienne Moshevich, editor of Alphastox.com, called "truly second to none in the industry."
In a note published following the announcement, Moshevich wrote, "DXD.V is one of my top picks for the year and through 2017. I love the way the market is reacting to the team's hard work and operational success thus far but please be sure they haven't even scratched the surface to what they hope to achieve over the next year. With a management team like theirs, this is only the beginning."
3D Signatures will focus on four areas in 2017. First, it plans to secure "validation and preliminary approval" of its prognostic test for Hodgkin's lymphoma patients. "The company expects to engage a nationally recognized and accredited laboratory partner in the validation and approval of a Hodgkin's Lymphoma Laboratory Developed Test (LDT) for Canada in 2017," 3D Signatures stated in its Oct. 17 press release.
The LDT presents a significant opportunity for the company as a "pathway to commercialization," Flowerday said, adding that the LDT partner could be announced within the next few months.
Second, the company will focus on its participation in the PRECISE study, "a major clinical trial for prostate cancer diagnosis and management." Determining the best treatment regime for an individual prostate cancer patient addresses a "significant unmet medical need," according to Flowerday. There is also a significant market opportunity, as 200,000 to 300,000 men annually in the United States are diagnosed with the disease annually. The 3D Signatures prognostic platform can also be used to track a patient's response to treatment using periodic follow-up blood tests, Flowerday explained.
3D Signatures' third focus is on developing "companion diagnostics" with other pharmas; the company stated it is "activating a dedicated strategy to engage industry in discussions around partnership opportunities."
Finally, 3D Signatures plans to cultivate relationships with "strategic academic and commercial partners, particularly in the United States," noting this will help in "expediting commercialization and maximizing market acceptance and penetration of its products."
"The company is rapidly moving towards mass commercialization of its products—products that do not require FDA approval and are therefore a bit of a novelty in the medical technology niche. . .its ultimate earning potential should be well in the $100m+ territory once things really get rolling." Angel Financial stated in an Oct. 4 report. "There is far more upside to be had before we're anywhere near done."
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) 3D Signatures Inc. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview or article until after it publishes.
Alphastox.com, 3D Signatures Inc.
Etienne Moshevich, chief editor of Alphastox, is the founder and president of Transcend Capital Inc., which is a shareholder of 3D Signatures and has been paid a fee by 3D Signatures.
Angel Publishing Investment Research
Details and Disclosures
Angel Publishing "would like our subscribers to know that any recommendation mentioned in our reports is NOT driven by advertisement from any sponsors. We are NOT affiliated with any company or investment we recommend, nor do we accept compensation from the companies we recommend. Our experts meticulously study the market trends and analyze companies' financial data in order to come up with the most profitable recommendations."